Clinical Trials Can Benefit Under-Represented Populations In Developing Countries

While conducting more clinical trials in developing countries can help under-represented populations benefit from new medical developments, trials in low-income settings face challenges such as complicated regulations, Trudie Lang of the Centre for Tropical Medicine at the University of Oxford and Sisira Siribaddana of the University of Rajarata and the Institute of Research & Development in Sri Lanka write in an essay published Tuesday in PLoS Medicine (6/12). According to a PLoS press release, “The authors conclude: ‘the globalization of clinical trials should not be about running inexpensive trial sites to benefit distant people, but should focus on bringing research to populations who have previously been under-represented in clinical trials, and enabling these same communities the benefits resulting from new drugs, vaccines, and improvements in managing health'” (6/12).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.